INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
iling Date		2006-09-21
irst Named Inventor	Joha	n H.A. GELISSEN
Art Unit		
Examiner Name		
Attorney Docket Number		US040094

				U.S.	PATENTS	Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	5881377	A	1999-03-09	GIEL			
	2	6288628	A	2001-09-11	FUJIMORI			
	3	5230074	A	1993-07-20	CANOVA			
	4	5664201	A	1997-09-02	IKEDEA			
	5	6035410	A	2003-03-07	EBESHU			
	6	6418536	A	2002-07-09	PARK			
	7	5910653	A	1999-06-08	CAMPO			
	8	6330676	B1	2001-12-11	KELSEY			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-09-21
First Named Inventor Joha		n H.A. GELISSEN
Art Unit		
Examiner Name		
Attorney Docket Number		US040094

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Rele	s,Columns,I vant Passag es Appear		
	1	20020042887	A1	2002-0	4-11	CHAUVEL					
	2	20020053684	A1	2002-0	5-09	CHAUVEL					
	3	20020055961	A1	2002-0	5-09	CHAUVEL					
	4	20020065049	A1	2002-0	5-30	CHAUVEL					
If you wis	h to a	dd additional U.S. Publi		-				d butto	Remove		
				FOREIG	SN PAT	TENT DOCUM			Pages,Colu		$\vdash$
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	ntry Kind P code4 D		Publication Date	Name of Patenter Applicant of cited Document		where Rele Passages Figures Ap	vant or Relevant	т.
	1	EP 0 936 793	EP		A	1999-08-18	NOKIA				
	2	EP 1 085 731	EP		A	2001-03-21	PIONEER CORP.				
	3	EP 1 096 360	EP		A1	2001-05-02	TEXAS INSTR.				
	4	EP 1 355 223	EP		A2	2003-10-22	MICROSOFT COR	tP.			

U.S.PATENT APPLICATION PUBLICATIONS

### 

	5	JP 05061574	JP		1993-03-12	NEC CORP	Abstract only	
	6	JP 2001086393	JP		2001-03-30	CANON INC.	Abstract only	
If you wis	h to a	ı dd additional Foreigr	n Patent Document	citation	information p	lease click the Add butto	on Add	_
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	miner Cita Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), polished.					Тs		
	1							
If you wis	h to a	dd additional non-pa	tent literature docu	ment ci	tation informat	ion please click the Add	button Add	
			EX	CAMINE	R SIGNATUR	E		
Examiner	Signa	ature				Date Considered		
						ormance with MPEP 60		

Take Kint Code of USPTO Petert Documents at Invest/ISPTO.000/c or MPEP 901.04. Tester of tice that issued the document, by the Involved on Social Code (WPO) Standard ST3.) "For Impresse patient comments, the includation of the year of the inspire or present be setted included the patient of the patient or inspired present and included the present of the patient or inspired in the inspired present and inspired the patient control of the patient or inspired." A find of document by the appropriate symbols as advantaged on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English languages thresidation is statistical."

# Application Number Filing Date 2006-09-21 Filing Date 2006-09-21 Filing Date Filing Date Filing Date 1006-09-21 Filing Date Filing Date Filing Date 1006-09-21 Filing Date Filing Date 1006-09-21 Filing Date

### CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 OFR 1.97(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(4)(2)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

.7 None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	Date (YYYY-MM-DD)	
Name/Drint	Registration Number	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.